Trial Profile
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pegargiminase (Primary)
- Indications Ewing's sarcoma; Osteosarcoma; Small cell lung cancer
- Focus Therapeutic Use
- 06 Dec 2022 Status changed from active, no longer recruiting to completed.
- 24 May 2022 Planned End Date changed from 31 Aug 2027 to 23 May 2027.
- 24 May 2022 Planned primary completion date changed from 31 Aug 2022 to 23 May 2027.